What is William Blair’s Estimate for CRSP Q1 Earnings?

CRISPR Therapeutics AG (NASDAQ:CRSP) – Stock analysts at William Blair cut their Q1 2025 EPS estimates for shares of CRISPR Therapeutics in a report released on Tuesday, February 11th. William Blair analyst S. Corwin now anticipates that the company will post earnings of ($1.05) per share for the quarter, down from their previous estimate of ($1.03). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.08) per share. William Blair also issued estimates for CRISPR Therapeutics’ Q2 2025 earnings at ($1.01) EPS, Q3 2025 earnings at ($1.32) EPS, Q4 2025 earnings at ($0.62) EPS, FY2025 earnings at ($4.00) EPS, Q1 2026 earnings at ($0.90) EPS, Q2 2026 earnings at ($0.90) EPS, Q3 2026 earnings at ($0.68) EPS, Q4 2026 earnings at ($0.17) EPS and FY2026 earnings at ($2.64) EPS.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%.

A number of other research analysts have also recently issued reports on the stock. Bank of America cut their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Truist Financial lifted their price objective on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday. Barclays boosted their target price on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Needham & Company LLC reissued a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday. Finally, StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Thursday. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $75.30.

CRISPR Therapeutics Stock Up 0.4 %

Shares of CRSP stock opened at $43.49 on Friday. The company has a market capitalization of $3.71 billion, a P/E ratio of -15.37 and a beta of 1.67. CRISPR Therapeutics has a 12-month low of $36.52 and a 12-month high of $91.10. The firm has a 50-day moving average price of $42.06 and a 200 day moving average price of $46.25.

Institutional Investors Weigh In On CRISPR Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CRSP. ARK Investment Management LLC grew its stake in shares of CRISPR Therapeutics by 19.7% during the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company’s stock worth $353,180,000 after acquiring an additional 1,474,439 shares in the last quarter. Capital International Investors boosted its holdings in CRISPR Therapeutics by 10.3% during the fourth quarter. Capital International Investors now owns 8,743,523 shares of the company’s stock worth $344,145,000 after purchasing an additional 816,789 shares during the last quarter. State Street Corp grew its position in CRISPR Therapeutics by 25.0% in the third quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after purchasing an additional 599,304 shares in the last quarter. FMR LLC grew its holdings in shares of CRISPR Therapeutics by 1.0% in the 3rd quarter. FMR LLC now owns 2,376,166 shares of the company’s stock valued at $111,632,000 after acquiring an additional 23,075 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of CRISPR Therapeutics by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company’s stock worth $68,329,000 after purchasing an additional 10,579 shares during the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

Insider Activity

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the sale, the chief executive officer now directly owns 181,540 shares in the company, valued at approximately $10,002,854. This trade represents a 7.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 4.10% of the stock is owned by company insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.